分组1 - Midea Group announced a cash dividend distribution plan for the 2025 mid-term A-shares, distributing 5 yuan per 10 shares, totaling 3.448 billion yuan [1] - Huayuan Communication is planning a change in control and will suspend trading of its stock starting November 12, 2025, for up to two trading days [2] - Shangwei New Materials reported a significant stock price increase of 1573.52% from July 9 to November 11, 2025, but its new intelligent robot business is still in the development stage and has not generated revenue [3] 分组2 - Shannon Chip announced that shareholder Shenzhen Xinlianpu pledged 1.27 million shares, accounting for 5.55% of its holdings and 0.27% of the total share capital [4] - Tianji Co., Ltd. reported that its controlling shareholder pledged 39.965 million shares for its own production and operation, representing 64.79% of its holdings and 7.97% of the total share capital [5] - ST Zhengping completed its stock trading situation review and will resume trading on November 12, 2025, with no significant changes in its production and operation [6] 分组3 - Furi Co. reported that its subsidiary Furi New Energy is facing risks of losses despite a 47.78% year-on-year increase in revenue to 168.3981 million yuan for the first three quarters of 2025 [7] - Wentai Technology announced that major shareholders reduced their holdings by 12.4443 million shares, completing the reduction plan [8] 分组4 - Anke Biotech signed a framework agreement for exclusive agency of PA3-17 injection, a CAR-T cell therapy product, in Greater China [9] - Tongxing Technology plans to invest approximately 3.2 billion yuan in a project to produce 100,000 tons of sodium-ion battery cathode materials and 6 GWh of battery cells [10] - Redik plans to establish a joint venture for the development of robotic components, with a registered capital of 100 million yuan [11] 分组5 - Haike New Source signed a strategic cooperation agreement with Kunlun New Materials for the purchase of 596,200 tons of electrolyte solvent over three years [12] - World announced that its diamond micro-drill products for PCB processing are still in the R&D phase and have not generated revenue [13] 分组6 - Xiamen Airport reported a 1.56% year-on-year increase in passenger throughput for October [14] - New City Holdings reported a 7.65% year-on-year increase in total commercial operating revenue for October [15] - Huadong Holdings announced a 0.65% year-on-year decrease in pig sales revenue for October [15] 分组7 - Keykai Technology's controlling shareholder plans to transfer 3% of its shares [15] - Zhongyou Engineering won a joint bid for a project worth approximately 3 billion yuan in Kazakhstan [15] - Weiteng Electric plans to raise no more than 300 million yuan through a private placement for smart manufacturing projects [15]

分组1 - Midea Group announced a cash dividend distribution plan for the 2025 interim A-shares, proposing a payout of 5 yuan for every 10 shares, totaling 3.448 billion yuan [2] - Huayuan Communication is planning a change in control and will suspend trading of its stock starting November 12, 2025, for up to two trading days [3] - Shangwei New Materials reported a significant stock price increase of 1573.52% from July 9 to November 11, 2025, but its new intelligent robot business is still in the product development stage and has not yet generated revenue [4] 分组2 - Shannon Chip announced that shareholder Shenzhen Xinlianpu has pledged 1.27 million shares, accounting for 5.55% of its holdings and 0.27% of the total share capital, for financing purposes [5] - Tianji Co., Ltd. disclosed that its controlling shareholder has pledged 39.965 million shares for its own production and operation, representing 64.79% of its holdings and 7.97% of the total share capital [6] - ST Zhengping completed its stock trading situation review and will resume trading on November 12, 2025, with no significant changes in its production and operation [7] 分组3 - Furi Co., Ltd. reported that its subsidiary Furi New Energy is facing a risk of losses despite a 47.78% year-on-year increase in revenue to 168.3981 million yuan for the first three quarters of 2025 [8] - Wentai Technology announced that major shareholders have reduced their holdings by 12.4443 million shares, completing the reduction plan [9] - Anke Biotech signed a framework agreement for exclusive agency of the PA3-17 injection product in Greater China, which is a CAR-T cell therapy for certain cancers [10] 分组4 - Tongxing Technology plans to invest approximately 3.2 billion yuan in a project to produce 100,000 tons of sodium-ion battery cathode materials and 6GWh battery cells [11] - Redick is collaborating with Aoyi Technology to establish a joint venture for the development of robotic components, with a registered capital of 100 million yuan [12] - Haike New Source signed a strategic cooperation agreement with Kunlun New Materials for the purchase of 596,200 tons of electrolyte solvent over a two-year period [13] 分组5 - World announced that its diamond micro-drills for PCB processing are still in the research and testing phase, with limited revenue impact [14][15] - Huadong Holdings reported a 0.65% year-on-year decline in pig sales revenue for October [16] - Keykai Technology's controlling shareholder plans to transfer 3% of its shares through an inquiry [17]

Core Viewpoint - Jinghua Pharmaceutical has received approval from the National Medical Products Administration for two drug registration certificates for its controlled-release capsules of carbidopa and levodopa, enhancing its product pipeline in the Parkinson's disease treatment sector [1] Group 1: Product Approval - The company is the third entity in China to obtain approval for the controlled-release capsules of carbidopa and levodopa (specification: carbidopa 50mg, levodopa 200mg) [1] - The controlled-release capsules (specification: carbidopa 25mg, levodopa 100mg) represent the first generic version in China, with the original product not registered for sale domestically [1] Group 2: Market Opportunities - The approval of the controlled-release capsules enriches the company's product offerings in the Parkinson's disease treatment field [1] - The introduction of the small specification product as the first generic in the domestic market provides the company with additional business opportunities in this niche market [1]

Core Viewpoint - The approval of the controlled-release formulation of Carbidopa-Levodopa by the National Medical Products Administration enhances the company's product pipeline in the Parkinson's disease treatment sector, particularly with the introduction of a first generic version in the domestic market [1] Group 1: Product Approval - The company received two drug registration certificates for Carbidopa-Levodopa controlled-release tablets [1] - The specifications for the approved products include Carbidopa 50mg and Levodopa 200mg, and Carbidopa 25mg and Levodopa 100mg [1] - The latter specification is the first generic version in China, as the original product has not been registered for sale domestically [1] Group 2: Market Impact - The approval enriches the company's offerings in the Parkinson's disease treatment market, providing a significant opportunity in a niche segment [1] - The controlled-release formulation is recognized as the "gold standard" for treating Parkinson's disease according to the "Chinese Parkinson's Disease Treatment Guidelines (2020 Edition)" [1] - The availability of the smaller dosage form improves medication convenience for patients with mild symptoms [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for two drug registration certificates for Carbidopa-Levodopa Extended-Release Tablets, enhancing its product pipeline in the Parkinson's disease treatment sector [1] Group 1: Product Approval - The Carbidopa-Levodopa Extended-Release Tablets (specification: Carbidopa 50mg, Levodopa 200mg) is the third approved product in the domestic market [1] - The Carbidopa-Levodopa Extended-Release Tablets (specification: Carbidopa 25mg, Levodopa 100mg) is the first generic version in the domestic market, with no original product registered for sale [1] Group 2: Market Opportunities - The approval of these products expands the company's opportunities in the Parkinson's disease treatment market [1] - The new products may lead to increased business prospects in this niche market [1] Group 3: Sales Uncertainty - The production and sales of the drugs may be influenced by changes in the market environment and other comprehensive factors, leading to certain uncertainties in sales performance [1]

公司卡左双多巴缓释片(规格：卡比多巴50mg、左旋多巴200mg)为国内第三家获批企业，卡左双多巴缓 释片(规格：卡比多巴25mg、左旋多巴100mg)则为国内首仿且该规格原研产品没有在国内进行注册销 售。 卡左双多巴缓释片的获批，丰富了公司在帕金森病治疗领域的产品管线，特别是其小规格产品成为国内 首仿，为公司在这一细分市场领域赢得了更多商机。卡左双多巴缓释片是左旋多巴与卡比多巴按4:1比 例组成的复方缓释制剂，被《中国帕金森病治疗指南(2020年版)》列为治疗帕金森病的"金标准"。公司 卡左双多巴缓释片的成功获批，为帕金森病患者提供了比较好的原研替代产品，其中小规格的获批，为 轻症患者的服药带来了便利性。 智通财经APP讯，精华制药(002349.SZ)发布公告，近日，公司收到国家药品监督管理局核准签发的卡左 双多巴缓释片的两个《药品注册证书》。 ...

证券代码：002349 证券简称：精华制药 公告编号：2025-047 精华制药集团股份有限公司 关于公司产品获得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或者重大遗漏。 近日，精华制药集团股份有限公司（以下简称"公司"）收到国家药品监督 管理局核准签发的卡左双多巴缓释片的两个《药品注册证书》，现就相关情况公 告如下： 一、药品注册批准情况 （1）证书编号：2025S03317 药品名称：卡左双多巴缓释片 主要成分：卡比多巴、左旋多巴 剂 型：片剂 申请事项：药品注册（境内生产） 包装规格：10 片/板，3 板/盒 处方药/非处方药：处方药 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、 标签及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求 方可生产销售。 上市许可持有人：精华制药集团股份有限公司 生产企业：精华制药集团股份有限公司 证券代码：002349 证券简称：精华制药 公告编号：2025-047 规 格：卡比多巴 25mg（按 C₁ ...

Group 1 - The company has decided to abolish the supervisory board and amend its articles of association accordingly, which was approved in the meetings held on August 28, 2025, and September 17, 2025 [2] - The company has completed the registration capital change and the cancellation of the supervisory board, obtaining a new business license from the Nantong Data Bureau [3] - The company's registered capital is approximately 829.67 million yuan, and it operates in various sectors including the production and sale of pharmaceuticals and health products [4] Group 2 - The company is located in Nantong City, Jiangsu Province, and was established on January 3, 1994 [4] - The legal representative of the company is Yin Hongyu [4] - The company’s business scope includes the production, processing, and sales of various pharmaceutical forms, as well as import and export activities related to its production needs [3]

证券日报网讯 10月30日晚间，精华制药发布公告称，公司于2025年8月28日召开第六届董事会第八次会 议和第六届监事会第七次会议，于2025年9月17日召开2025年第一次临时股东会审议通过了《关于修改 公司章程的议案》，公司不再设监事会，并相应修订《公司章程》中有关注册资本、监事会等内容。近 日，公司完成了注册资本变更、取消监事会的工商变更登记和《公司章程》备案手续，并取得了南通市 数据局换发的《营业执照》。 （文章来源：证券日报） ...

证券代码：002349 证券简称：精华制药 公告编号：2025-046 精华制药集团股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、基本情况 精华制药集团股份有限公司（以下简称"公司"）于2025年8月28日召开第六 届董事会第八次会议和第六届监事会第七次会议，于 2025年9月17日召开2025年 第一次临时股东会审议通过了《关于修改公司章程的议案》，公司不再设监事会， 并相应修订《公司章程》中有关注册资本、监事会等内容。具体内容详见公司于 2025年8月30日发布在指定披露媒体上的《关于修改公司章程的的公告》。 4、住所：南通市港闸经济开发区兴泰路9号 5、法定代表人：尹红宇 6、注册资本：82967.4908万元整 7、成立日期：1994年1月3日 8、经营范围：生产、加工、销售：片剂、丸剂、散剂、冲剂、颗粒剂、胶囊 剂、注射剂、糖浆剂、煎膏剂、酒剂、滋补保健品、药茶、饮料、口服液、合剂; 包装材料及相关技术的进出口业务；经营本企业生产、科研所需要的原辅料、药 材、农副产品（除专营）、机械设备、 ...